Bausch + Lomb announced that it has received CE Mark from the European Commission for the Stellaris Elite Vision Enhancement System, the company’s next-generation ophthalmic surgical platform, which includes Vitesse, the first and only hypersonic, open-port vitrectomy system.
The Stellaris Elite platform is now available throughout greater Europe, including the 28 countries of the European Union, Iceland, Liechtenstein, Norway, and Switzerland.
“We’re pleased to bring the Stellaris Elite Vision Enhancement System, including the cutting-edge Vitesse technology, to the greater European market,” Joseph C. Papa, chairman and CEO, Valeant, said in a company news release. “Because this surgical platform offers the opportunity to continuously add innovative upgrades and enhancements, it enables surgeons to customize their systems and expand their capabilities as their needs evolve without having to invest in a new surgical system.”
Already available in the United States, the Stellaris Elite Vision Enhancement System is the first phacoemulsification platform to offer Adaptive Fluidics, which combines precise aspiration control with predictive infusion management to create a highly responsive and controlled surgical environment for efficient lens removal. As part of the platform’s vitreoretinal capabilities, the Vitesse hypersonic vitrectomy system uses a novel, single-needle design and continuously open-port system that represents the first major advancement in vitreous removal in 40 years. Vitesse will be available exclusively on the Stellaris Elite platform.